EyeGene Inc is a Korea-based company primarily engaged in research and development in the medical and pharmaceutical fields. The Company is mainly engaged in the research and development of messenger ribonucleic acid (mRNA)-based vaccines. The Company also develops novel treatments for ophthalmic diseases, including treatments for macular degeneration and diabetic retinopathy, as well as adeno-associated virus (AAV) gene therapy targeting rare retinal diseases. In addition, the Company develops a quadrivalent meningococcal vaccine and recombinant botulinum toxin.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-08	₩2,090.00	+3.47%	198,902
26-09-07	₩2,020.00	+1.51%	100,647
26-09-04	₩1,990.00	+2.58%	105,383
26-09-03	₩1,940.00	+0.73%	106,541
26-09-02	₩1,926.00	+1.16%	146,828

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 2026-09-08			5-day change	1st Jan Change
2,090.00 ^KRW	+3.47%		+9.77%	+20.18%

09-04	MVRIX Co., Ltd. announced that it has received KRW 8 billion in funding from InterVest, Korea Investment Partners Co. Ltd., EyeGene Inc., Korea Omega Investment Corp, Lifecore Partners, SNU Technical Holdings	CI
25-09-16	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE

Market Cap	90.35B 67.34M 57.9M 54.47M 49.71M 92.76M 6.38B 93.24M 645M 250M 3.26B 253M 247M 10.38B	P/E 2024	-5.71x	P/E 2025	-3.1x
Enterprise Value	45.41B 33.85M 29.1M 27.38M 24.99M 46.63M 3.21B 46.87M 324M 126M 1.64B 127M 124M 5.22B	EV / Sales 2024	11.6x	EV / Sales 2025	8.48x
Free-Float	70.86%	Yield 2024 *	-	Yield 2025	-

09-04	MVRIX Co., Ltd. announced that it has received KRW 8 billion in funding from InterVest, Korea Investment Partners Co. Ltd., EyeGene Inc., Korea Omega Investment Corp, Lifecore Partners, SNU Technical Holdings	CI
25-09-16	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE
23-12-20	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
23-12-12	EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
23-05-15	EyeGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-03-15	EyeGene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-04-07	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
21-10-04	Maravai LifeSciences : Says Unit TriLink To Supply Proprietary Technology to EyeGene for Production of COVID-19 Vaccine	MT
21-09-20	EyeGene Inc.(KOSDAQ:A185490) added to S&P Global BMI Index	CI
20-09-17	EyeGene Inc. announced that it has received KRW 22 billion in funding from a group of investors	CI
20-09-15	EyeGene Inc. announced that it expects to receive KRW 22 billion in funding from a group of investors	CI
19-09-23	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
18-09-27	EyeGene Inc. announced that it has received KRW 29.9998664 billion in funding from Meritz Securities Co., Ltd., Investment Arm, IBK Capital Corporation, Korea Investment & Securities Co., Ltd., Investment Arm	CI

1 day	+3.47%
1 week	+9.77%
Current month	+9.54%
1 month	+24.78%
3 months	+43.74%
6 months	+59.79%
Current year	+20.18%

EyeGene Inc. Stock

Stocks

A185490

KR7185490000

Pharmaceuticals

Valuation : EyeGene Inc.

Chart: EyeGene Inc.

Latest news : EyeGene Inc.

Quotes and Performance

Price Extremes

Managers and Directors : EyeGene Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	1,905	2,165
1 month	1,636	2,305
Current year	1,182	2,805
1 year	1,182	2,915
3 years	1,182	4,895
5 years	1,182	48,000
10 years	1,182	60,200

Manager	Title	Age	Since
Suk-Keun Choi CEO	Chief Executive Officer	59	2024-02-19
Myeong-Jae Lee DFI	Director of Finance/CFO	57	2012-04-30
Won-Il Yoo PSD	President	63	2000-06-22

Director	Title	Age	Since
Won-Il Yoo BRD	Director/Board Member	63	2000-06-22
Myeong-Jae Lee BRD	Director/Board Member	57	2024-02-19
Dal-Hyun Kim BRD	Director/Board Member	64	2022-05-12

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/10/24	Kwang-In Lee	Buy		8,019	0.0297%
4/10/24	Kwang-In Lee	Buy		12,297	0.0455%
3/12/24	Won-Il Yoo	Buy	Chairperson	1,000	0.0037%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EYEGENE INC.	+3.47%	+9.77%	-27.43%	-45.57%	67.34M
ELI LILLY AND COMPANY	-2.21%	-3.11%	+52.16%	+91.64%	1,002B
JOHNSON & JOHNSON	-2.22%	-0.76%	+51.08%	+67.61%	649B
ABBVIE INC.	-2.99%	-4.31%	+18.59%	+66.94%	440B
ROCHE HOLDING AG	-0.36%	0.00%	+29.48%	+37.53%	346B
NOVARTIS AG	-0.41%	-15.08%	+9.27%	+26.28%	263B
ASTRAZENECA PLC	-1.23%	-1.95%	-1.95%	+11.81%	250B
AMGEN INC.	-10.08%	-10.26%	+40.32%	+51.55%	213B
NOVO NORDISK A/S	-1.12%	-4.19%	-14.67%	-57.74%	201B
GILEAD SCIENCES, INC.	-2.88%	-2.19%	+26.54%	+92.95%	182B
Average	-1.12%	-1.00%	+18.34%	+34.30%	354.37B
Weighted average by Cap.	-0.70%	-2.39%	+32.78%	+57.62%

	2024	2025
Net sales	3.36B 2.5M 2.15M 2.02M 1.85M 3.45M 237M 3.46M 23.97M 9.27M 121M 9.39M 9.19M 386M	3.57B 2.66M 2.29M 2.15M 1.96M 3.66M 252M 3.68M 25.48M 9.86M 129M 9.98M 9.76M 410M
Net income	-12.13B -9.04M -7.77M -7.31M -6.67M -12.45M -857M -12.52M -86.63M -33.52M -438M -33.94M -33.2M -1.39B	-15.71B -11.71M -10.06M -9.47M -8.64M -16.13M -1.11B -16.21M -112M -43.4M -567M -43.96M -43M -1.81B
Net Debt	-30.11B -22.44M -19.29M -18.15M -16.56M -30.91M -2.13B -31.07M -215M -83.2M -1.09B -84.26M -82.42M -3.46B	-44.94B -33.49M -28.8M -27.09M -24.72M -46.14M -3.18B -46.38M -321M -124M -1.62B -126M -123M -5.16B